COMPANY

Ophidion

Ophidion, Inc. is an early-stage CNS biopharmaceutical company built around a proprietary, non-invasive carrier technology that enables direct delivery of gene-silencing agents and other therapeutics across the blood-brain barrier into the brain. From company website Source · Oct 13, 2026

Keywords: biopharmaceutical therapeutics

Profile checked Oct 10, 2026

7NIH grants

NIH awards 7

Annual award amounts. Total $2.2M.

May 18, 2016 NIH award 5R44DA032464-03 FY2016: $407,007 awarded for that fiscal year; activity R44 (SBIR); PI ANGENIEUX, BRIGITTE; recipient as written: OPHIDION, INC., PASADENA, CA. Development of a5 nicotinic receptor agonists source ↗
Apr 27, 2015 NIH award 2R44DA032464-02A1 FY2015: $386,184 awarded for that fiscal year; activity R44 (SBIR); PI ANGENIEUX, BRIGITTE; recipient as written: OPHIDION, INC., PASADENA, CA. Development of a5 nicotinic receptor agonist source ↗
May 26, 2012 NIH award 5R43MH094004-02 FY2012: $328,348 awarded for that fiscal year; activity R43 (SBIR); PI ANGENIEUX, BRIGITTE; recipient as written: OPHIDION, INC., PASADENA, CA. siRNA Mediated Modulation of Lynx1 for Cogniti source ↗
Aug 22, 2011 NIH award 1R41DA032464-01 FY2011: $296,028 awarded for that fiscal year; activity R41 (STTR); PI ANGENIEUX, BRIGITTE; recipient as written: OPHIDION, INC., PASADENA, CA. In vivo and in vitro tools to target CHRNA5 fo source ↗
Jun 3, 2011 NIH award 1R43MH094004-01 FY2011: $328,017 awarded for that fiscal year; activity R43 (SBIR); PI WALZ, ANDREAS; recipient as written: OPHIDION, INC., PASADENA, CA. Biologic approach to targeting a nicotinic receptor source ↗
Feb 4, 2009 NIH award 5R43MH083416-02 FY2009: $250,000 awarded for that fiscal year; activity R43 (SBIR); PI WALZ, ANDREAS; recipient as written: OPHIDION, INC., PASADENA, CA. Improved Cell Line and Assay Development of Nicotini source ↗
Jun 11, 2008 NIH award 1R43MH083416-01 FY2008: $250,000 awarded for that fiscal year; activity R43 (SBIR); PI WALZ, ANDREAS; recipient as written: OPHIDION, INC., PASADENA, CA. Improved Cell Line and Assay Development of Nicotini source ↗